Pharma firms to tap market for cancer drug Herceptin

Various Pharma companies are planning to tap Rs 130-crore market for breast cancer drug Herceptin, media report says. Reports said that Dr Reddy’s Laboratories Ltd and Intas Pharmaceuticals Ltd are planning to launch biosimilar of Herceptin (trastuzumab) and the trials are likely to start soon. While Biocon, is likely to launch the product this financial year. DRL spokesperson said: “Dr Reddy’s does not share specifics of its portfolio. However, molecules like trastuzumab are very much on our radar.”